A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic (IV) Non-Small-Cell Lung Cancer. (OSE2101C301)

Trial Profile

A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic (IV) Non-Small-Cell Lung Cancer. (OSE2101C301)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs OSE 2101 (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATALANTE-1
  • Sponsors OSE Immunotherapeutics; OSE Pharma
  • Most Recent Events

    • 16 Aug 2017 Last checked against European Clinical Trials Database.
    • 11 Aug 2017 Status changed from suspended to active, no longer recruiting.
    • 23 Jun 2017 According to an OSE Immunotherapeutics media release, on the recommendation by IDMC, company is temporarily pausing patient accrual while continuing treatment for patients already enrolled due to an emerging benefit/risk balance of the experimental treatment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top